

Supplemental Table for:

U.S. Food and Drug Administration Approval Summary: Pembrolizumab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer whose Tumors Express Programmed Death-Ligand 1 (PD-L1)

Richard Pazdur et al.

Table S1. Keynote 001 Study Parts

<b>Study Parts</b>	<b>Pembrolizumab Doses</b>	<b>Patient Population</b>	<b>N</b>
<b>A</b>	Dose-escalation	Solid tumors	28
<b>B</b>	10 mg/kg q2W	Melanoma	506
	10 mg/kg q3W	(ipilimumab naïve, refractory)	
	2 mg/kg q3W		
<b>C</b>	10 mg/kg q3W	3L+ NSCLC	38
<b>D</b>	10 mg/kg q3W	Melanoma	88
	2 mg/kg q3W	(ipilimumab naïve)	
<b>F</b>		NSCLC	11
	F1 (Amendment 6)	10 mg/kg q3W 2 mg/kg q3W	
F1 (Amendment 7)	10 mg/kg q3W	NSCLC, 1L, PDL1+	90
	10 mg/kg q2W		
F2 (Amendment 6)	10 mg/kg q3W	NSCLC, 3L+, PDL1+	33
F2 (Amendment 7)	10 mg/kg q2W	NSCLC, 2L+, PDL1+	280
	10 mg/kg q3W		
F2 (Amendment 7)	10 mg/kg q2W	NSCLC, 3L+, PDL1-	43
F3 (Amendment 9)	2 mg/kg q3W	NSCLC, 2L+, PDL1+	55

Abbreviations: q2W: every 2 weeks, q3W: every 3 weeks, 1L: first-line treatment, 2L+: second-line treatment or greater, 3L+: third-line treatment or greater